Skip to main content
Smart Investors Daily
Eli Lilly and Company logo

NYSE · LLY

Eli Lilly and Company

Healthcare · Drug Manufacturers - General

$1,351.12

Up+$2.88 (+0.21%)

Updated Nov 20, 2026, 5:43 PM

SID Score

6.8/10

Composite research score

Smart Money

44/100

Neutral

Market cap
906.5B
P/E ratio
49.16
Dividend yield
0.57%
52-week range
$850.51 – $1,475.25
Volume
3.2M
Avg. volume
3.8M

Price performance · LLY

LLY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

LLY closed at $1,351.12 after 21 trading sessions, up 3.40% for the selected period.

Last close
$1,351.12
Period change
+3.40%
Period low
$1,273.46
Period high
$1,443.50
Daily close
View OHLC price history
LLY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$1,369.38$1,382.00$1,341.46$1,351.123.2M
Nov 18, 2026$1,407.93$1,423.11$1,380.00$1,382.752.88M
Nov 17, 2026$1,415.995$1,432.2799$1,401.66$1,415.552.65M
Nov 16, 2026$1,453.75$1,475.25$1,427.66$1,431.673.21M
Nov 13, 2026$1,429.91$1,449.64$1,419.77$1,443.502.08M
Nov 12, 2026$1,446.55$1,460.00$1,427.28$1,427.282.41M
Nov 11, 2026$1,418.08$1,440.47$1,414.37$1,437.291.88M
Nov 10, 2026$1,408.49$1,438.88$1,400.00$1,432.293.02M
Nov 9, 2026$1,365.395$1,419.67$1,364.5829$1,411.954.03M
Nov 6, 2026$1,350.45$1,377.2771$1,333.22$1,354.003.81M
Nov 5, 2026$1,434.00$1,453.00$1,364.73$1,364.734.89M
Nov 4, 2026$1,440.00$1,445.96$1,401.59$1,417.993.64M
Nov 3, 2026$1,399.63$1,437.00$1,393.47$1,409.382.84M
Nov 2, 2026$1,393.15$1,421.99$1,382.02$1,410.993.74M
Oct 30, 2026$1,428.83$1,449.68$1,408.36$1,417.545.25M
Oct 29, 2026$1,332.73$1,408.38$1,330.00$1,373.704.37M
Oct 28, 2026$1,268.55$1,299.43$1,260.34$1,288.302.06M
Oct 27, 2026$1,273.50$1,297.92$1,272.0703$1,281.911.85M
Oct 26, 2026$1,286.39$1,296.90$1,273.7293$1,279.142.11M
Oct 23, 2026$1,304.15$1,307.9199$1,257.62$1,273.462.28M
Oct 22, 2026$1,281.76$1,321.21$1,275.10$1,306.692.66M

Latest LLY news

The latest Smart Investors Daily articles mentioning LLY.

LLY research

Overview

Company profile and research snapshot.

Company profile

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$1,055.92
Implied upside
—
Analysts
21
LLY recent ratings
DateFirmRatingTarget
Nov 17, 2026RBC CapitalOutperform—
Nov 16, 2026BarclaysOverweight—
Nov 9, 2026JefferiesBuy—
Nov 2, 2026Cantor FitzgeraldOverweight—
Oct 30, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

Eli Lilly and Company Stock Performance

Eli Lilly and Company shares traded at $1,382.54, reflecting a daily decline of 1.66% per SID market data. Despite the session pullback, the stock has demonstrated strong momentum across multiple timeframes, posting gains of 14.13% over the past month, 10.56% over three months, and 31.89% over the trailing twelve months. LLY currently trades well above both its 50-day moving average of $1,252.56 and its 200-day moving average of $1,111.25, confirming a sustained bullish technical trend. The 14-day relative strength index stands at 68.3, approaching but not yet breaching the traditional overbought threshold of 70. The company carries a market capitalization of approximately $906.5 billion, positioning it among the largest healthcare companies globally. Notably, LLY exhibits a beta of 0.369, according to SID market data, indicating significantly lower volatility relative to the broader market, a characteristic common among large-cap pharmaceutical stocks.

Eli Lilly and Company Valuation Analysis

Eli Lilly trades at a price-to-earnings ratio of 49.16, a substantial premium to the broader healthcare sector, reflecting the market's pricing of robust future growth expectations tied to its GLP-1 receptor agonist portfolio, per SID market data. The PEG ratio stands at 1.47, suggesting the valuation remains elevated even when adjusting for projected earnings growth, though it falls within a range some frameworks consider reasonable for high-growth companies. The price-to-book ratio of 38.04 further underscores the significant premium investors are paying relative to the company's net asset value, according to SEC filings. Eli Lilly offers a modest dividend yield of approximately 0.59%, positioning it as a growth-oriented holding rather than an income play. Within the healthcare sector, these valuation multiples rank among the highest, consistent with LLY's status as a leading beneficiary of expanding demand for diabetes and obesity therapeutics driving top-line acceleration.

Smart Money Activity for LLY

Eli Lilly's composite smart money score stands at 42 out of 100 with a neutral signal, reflecting a mixed picture across institutional and insider activity categories, per SID market data. Institutional positioning scores a perfect 25 out of 25, indicating maximum conviction among large asset managers and mutual funds holding significant stakes in the company, according to 13F institutional filings. In contrast, the insider trading component scores 4.1 out of 25 despite notable recent activity — 20 insider transactions were recorded over the past 90 days, with 15 purchases and 5 sales, according to SEC Form 4 filings. The buy-to-sell ratio of 3-to-1 suggests insiders have been net accumulating shares. Dark pool activity scores 9.3 out of 25, indicating moderate but unremarkable off-exchange institutional interest. Congressional trading activity registers at a low 3.2 out of 25. The divergence between strong institutional ownership signals and weaker insider and congressional scores produces the overall neutral composite reading.

Eli Lilly and Company Earnings Outlook

Eli Lilly has delivered a consistent pattern of earnings beats across its three most recent reported quarters, according to company earnings reports. In the most recently reported period, the company posted earnings per share of $7.48 against a consensus estimate of $6.36, representing a positive surprise of $1.12. The prior quarter saw an even larger beat, with actual EPS of $8.38 versus the $6.01 estimate, a $2.37 upside surprise. The quarter before that produced EPS of $8.55 against a $6.85 estimate, a $1.70 beat. These three consecutive quarters of substantial outperformance indicate that analyst models have consistently underestimated the company's earnings power. Looking ahead, the upcoming quarter carries a consensus estimate of $8.84, per analyst estimates. The magnitude of recent surprises — averaging $1.73 per share across the last three quarters — suggests analysts may still be calibrating their models to the company's accelerating revenue trajectory.

Wall Street Analyst Ratings for LLY

Wall Street consensus on Eli Lilly remains unanimously bullish, with all five most recent analyst actions reiterating positive ratings, according to Wall Street analyst reports. On November 17, RBC Capital maintained its Outperform rating, following Barclays' reiteration of Overweight on November 16. Jefferies reaffirmed its Buy rating on November 9, while Cantor Fitzgerald maintained Overweight on November 2, per SID consensus data. RBC Capital had also previously reiterated Outperform on October 30, issuing two positive notes within an 18-day span. Notably, none of the recent actions reflect upgrades — all five represent reiterations of existing positive positions, indicating sustained rather than newly emerging bullish conviction. The absence of any Hold, Underweight, or Sell ratings among recent coverage actions underscores the degree of analyst alignment around the LLY growth thesis. The consistency across multiple major firms — including both bulge-bracket and independent research houses — reflects broad institutional confidence in the company's commercial and pipeline trajectory.